Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wearable sensors could transform CMT1A monitoring

NCT ID NCT07591779

Not yet recruiting Knowledge-focused Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will use wearable activity trackers to measure how much people with Charcot-Marie-Tooth disease type 1A (CMT1A) move at home. Researchers want to see if sensor data matches standard clinical tests. The goal is to improve patient follow-up and support future trials of new treatments like Nano-Cur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to monitor CMT1A progression at home and help design future treatment trials.
What could go wrong
This is an observational study, not a treatment trial. It may not directly improve patient outcomes, and sensor accuracy could vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHARCOT-MARIE-TOOTH DISEASE, TYPE IA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Charcot-Marie-Tooth disease Charcot-Marie-Tooth disease type 1A hereditary peripheral neuropathy Mobility Limitation Motor Activity neuromuscular disease peripheral nervous system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHARCOT-MARIE-TOOTH DISEASE, TYPE IA MOTOR ACTIVITY NEUROMUSCULAR DISEASES PERIPHERAL NEUROPATHY HEREDITARY WALKING, DIFFICULTY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Chu de Limoges

    Limoges, 87042, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.